Anuh Pharma Ratios

Anuh Pharma Ltd Ratios

The Anuh Pharma Ltd Ratios page provides a complete fundamental analysis of Anuh Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Anuh Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Anuh Pharma Ltd (NSE: ANUHPHR, BSE: 506260) is currently trading at ₹78.25, with a market capitalization of ₹7.69B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Anuh Pharma Ltd remains a key stock for fundamental analysis using Anuh Pharma Ltd Ratios.

Anuh Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Anuh Pharma Ltd P/E ratio currently stands at 15.75, making it one of the most tracked metrics in Anuh Pharma Ltd Ratios.

Historically, the Anuh Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 15.75
• 2023: 20.49
• 2022: 11.03
• 2021: 14.09
• 2020: 15.91

The decline in Anuh Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Anuh Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.29.

Historical P/B trend:

• 2024: 2.29
• 2023: 4.23
• 2022: 1.65
• 2021: 2.01

Anuh Pharma Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Anuh Pharma Ltd P/S ratio currently stands at 1.13, an important part of Anuh Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.13
• 2023: 1.90
• 2022: 0.76
• 2021: 0.89

A stable or declining Anuh Pharma Ltd P/S ratio indicates cautious market sentiment.

Anuh Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Anuh Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 19.58.

Historical Anuh Pharma Ltd Price to Cash Flow Ratio:

• 2024: 19.58
• 2023: 89.03
• 2022: 7.18
• 2021: 14.31
• 2020: 0

The declining Anuh Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Anuh Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Anuh Pharma Ltd EV currently stands at ₹6.83B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 6.83B
• 2023: 11.69B
• 2022: 3.42B
• 2021: 3.98B

Anuh Pharma Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Anuh Pharma Ltd EV/EBITDA ratio is currently 10.62, a key metric in Anuh Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 10.62
• 2023: 15.22
• 2022: 6.25
• 2021: 8

Stable Anuh Pharma Ltd EV/EBITDA indicates balanced valuation.

Anuh Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Anuh Pharma Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.01
• 2022: 0
• 2021: 0.02

Anuh Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Anuh Pharma Ltd ROE currently stands at 15.34%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 15.34
• 2023: 22.56
• 2022: 15.90
• 2021: 15.11

Anuh Pharma Ltd maintains stable profitability levels.

Anuh Pharma Ltd Ratios Analysis Summary

The Anuh Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Anuh Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Anuh Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.